Iambic Therapeutics vs Relay Therapeutics
Two clinical stage companies whose platforms attack the same limitation from different angles: that a static picture of a protein is a poor guide to whether a molecule will bind it. Relay built its whole thesis on motion, arguing that binding sites appear only in particular conformational states and that discovery anchored to fixed structures misses targets entirely, with multiple oncology programmes in humans and a public listing behind it. Iambic is physics informed in a different sense, with two named model families predicting protein ligand structure and cellular activity, its core method in peer review, released code, and a platform derived molecule with human data. Iambic is the more inspectable platform. Relay is the more advanced pipeline. Both should be judged on the molecules, because that is the only evidence that distinguishes a real platform from a good story.
- The core method is in peer review rather than in marketing, with two named model families doing the work, one for protein ligand structure prediction and one for predicting activity from molecular structure.
- It has a platform derived molecule with human data, which is the strongest evidence class available in this category and one few reach.
- Released code and publications give a partner something to evaluate technically rather than a demonstration to watch.
- The scientific thesis is the differentiator rather than the model: proteins move, binding sites appear only in particular conformational states, and a static structure approach misses targets that motion reveals.
- It is clinical stage with multiple oncology programmes in humans and listed on a public exchange, so both the pipeline and the finances are disclosed.
- The reciprocal design between computation and experiment is structural, with predictions tested and results feeding back rather than models running ahead of the laboratory.
Side by Side
| Axis | I Iambic Therapeutics |
R Relay Therapeutics |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both are clinical stage companies rather than software vendors, so a partner is buying a relationship and a pipeline rather than a tool, and the meaningful comparison is programmes in humans rather than platform description. Relay explains its scientific thesis clearly and its computational method not at all, which is the inverse of Iambic's position.
Neither publishes a security attestation, and neither needs the provider oriented axes in this index, which are scoping determinations rather than gaps. Judge both on assets that clear human trials, since every AI discovery platform looks convincing until the molecules meet patients.